Dr. Chilton has over four decades of experience in radiopharmaceutical science and nuclear pharmacy that spans academia, operational technologies, clinical research, and corporate business development.
As a VP with PETNet Solutions, and Cardinal Health’s Nuclear Pharmacy Services, he led and developed successful collaborations with academia and pharma in the creation of enduring partnerships and commercial and research ventures, as well as successful strategies around the development and launch of several diagnostic imaging and therapeutic radiopharmaceuticals. During his tenure with Wake Forest University’s School of Medicine, Division of Radiological Sciences, he was recognized as one of the “Twenty-five Pioneers of Nuclear Pharmacy” by the American Pharmaceutical Association (APhA). He was a member of the Committee on Revision, and expert committees of the United States Pharmacopeia (USP), was elected and appointed to several positions in the Society of Nuclear Medicine and Molecular Imaging (including receiving the SNM Presidential Distinguished Service award). Dr. Chilton served as a member of the editorial board of the Journal of Nuclear Medicine for 10 years; is a past president of the American Board of Science in Nuclear Medicine (ABSNM), and a Diplomate of the ABSNM. He was also recognized as a Fellow of the American Society of Healthcare Pharmacists (ASHP). Dr. Chilton received his B.S. degree in Pharmacy from Mercer University’s School of Pharmacy, Doctor of Pharmacy from the University of Tennessee Health Sciences Center, and a Master of Business Administration from the Babcock School of Management, Wake Forest University.
Robert P. Fitzsimmons is a founding member of CereMark Pharma LLC, and practices as a trial attorney with the Fitzsimmons Law Firm PLLC in Wheeling, West Virginia. He has been actively involved in brain injury research for over 20 yrs.
Bob successfully represented Pittsburgh Steeler and NFL Hall of Famer Mike Webster in his disability lawsuit against the NFL beginning in 1997. This was the first time anyone had alleged and proven that traumatic football-related activities had caused brain injury (Chronic Traumatic Encephalopathy, CTE).
Mr Fitzsimmons, Dr Julian Bailes and Dr Bennet Omalu founded the Brain Injury Research Institute (BIRI) in 2007 and together with Dr Jenn Hammers serve as Co-Directors. Bob received a B.S. degree from Allegheny College in Meadville, Pennsylvania, and his Juris Doctorate Degree from the University of Baltimore School of Law.
Dr. Putnam earned his Regulatory Affairs Certification (United States) in 2007 from the Regulatory Affairs Professional Society (RAPS) and is a routine contributor to the RAPS’ publication Fundamentals of US Regulatory Affairs.
Dr. Putnam was previously the General Manager of Cardinal Health Regulatory Sciences where he led Cardinal Health’s scientific and regulatory consulting business unit which included more than 200+ regulatory affairs associates. As part of Cardinal Health Regulatory Sciences, Dr. Putnam played an integral role in the development and approval of dozens of pharmaceutical, biologic and medical device products. Dr. Putnam earned a PhD and MA in Organic Chemistry from Washington University in St. Louis where his research focused on drug discovery of therapeutic oligonucleotides. Dr. Putnam is now a Professor of Pharmacy Practice, Director of the Clinical Pharmacology and Experimental Therapeutics Center, School of Pharmacy, Texas Tech Health Sciences Center, Dallas TX.
Bennet Omalu is an internationally renowned pathologist with five specialty board certifications in anatomic pathology, clinical pathology, forensic pathology, neuropathology and medical management.
He is a Certified Physician Executive and holds a Masters in Public Health in Epidemiology, and a Masters in Business Administration from the Tepper School of Business, Carnegie Mellon University. He is currently a Clinical Professor of Medical Pathology and Laboratory Medicine at the University of California, Davis. Dr. Omalu has performed over seven thousand autopsies and examined over eight thousand brains in his career, especially brains involving all types of brain trauma. Beginning in 2002, he was the first to identify and name CTE in American football players, professional wrestlers and retired military veterans. His work has advanced research and universal understanding of traumatic brain injury, and has been featured in countless local, national and international print and electronic news media and documentary and feature films. In August 2019 Dr Omalu was recognized by Sports Illustrated as one of the “100 Figures Who Shaped the NFL’s First Century”
Billy West has been a practicing attorney in Louisiana for 32 years with an active practice in all areas of civil and criminal law, and has collaborated with Dr. Julian Bailes regarding the safety of athletes across the spectrum of football from Pop Warner to collegiate level of play, including return-to-play protocols, and second impact syndrome.
In his distinguished career, he has represented numerous professional athletes and coaches. Mr. West was formerly a member of the NFLPA, served on the Board of Directors of the Mainstay Independence Bowl, and has been recognized as a Distinguished Alumni of Louisiana State University. Mr. West has hosted sports related radio shows for years in Louisiana and has been a frequent color commentator for High School and Collegiate radio and television broadcasts. Mr. West is passionate about team sports and their positive effects on society and has been an advocate of innovative approaches to athletes’ safety. Mr. West received his B.A. degree from Louisiana State University in 1982 and his J.D. from Southern University in 1988.
Gary Small is Chair of Psychiatry at Hackensack University Medical Center and Physician in Chief for Behavioral Health at Hackensack Meridian Health, New Jersey’s largest, most integrated health system.
Prior to joining Hackensack Meridian Health, Dr. Small was a professor of psychiatry and biobehavioral sciences, Parlow-Solomon professor on aging at the David Geffen School of Medicine at UCLA, director of the Division of Geriatric Psychiatry at the Semel Institute for Neuroscience & Human Behavior, and director of the UCLA Longevity Center. He is a co-inventor of F-18 FDDNP PET, and his NIH-supported research has helped influence Medicare policy on PET scan reimbursements for diagnosing Alzheimer’s disease. Dr. Small received his B.S. degree from UCLA and earned his M.D. from the University of Southern California. He completed a psychiatry residency at Massachusetts General Hospital, a clinical fellowship at Harvard Medical School, and geriatric psychiatry training at UCLA. Dr. Small has authored over 500 scientific works and received numerous awards and honors, including the Weinberg Award for Excellence in Geriatric Psychiatry from the American Psychiatric Association. In 2002, Scientific American magazine named him one of the world’s top innovators in medical diagnostics.
Mr. Cook is an attorney and sports agent with 44 years experience as a practicing attorney and 27 years as a Certified Contract Advisor or Sports Agent, with an extensive history of representation of athletes in the field of football.
Mr. Cook has built a reputation unparalleled in contract negotiations, which have resulted in multiple record-breaking, landmark contracts, including the NFL’s first $100 million contract for Brett Favre, and the innovative guaranteed payment structure for Calvin Johnson’s record-setting rookie contract with the Detroit Lions. Mr. Cook has represented the number one selection in the NFL Draft three times out of the last eight years, Cam Newton, Jadeveon Clowney and Myles Garrett. Mr. Cook received his B.S. Degree in Business Administration from The American University in Washington, D.C. in 1970, and his Juris Doctorate Degree from the University of Mississippi School of Law in 1974. He is a Certified Contract Advisor with the NFLPA and MLBPA. He is the Founder and President of B. C. Sports, Inc. and a native of Man, West Virginia.
Jorge Barrio is Professor Emeritus of Molecular and Medical Pharmacology at the David Geffen UCLA School of Medicine.
Along with other UCLA scientists, he pioneered the development of PET technology and new imaging approaches to investigate the biochemical mechanisms of neurodegenerative diseases. He is the inventor of F-18 FDDNP, the first imaging method to visualize tau pathology in the brain of living subjects. Dr. Barrio has received numerous honors, including the Paul Aebersold Award for Outstanding Achievements in Basic Sciences. In 2011, in recognition of his achievements, the Annual “Jorge Barrio Lecture for Advances in Clinical Sciences” was instituted by the World Molecular Imaging Congress (WMIC). He is the founding Editor-in-Chief of Molecular Imaging and Biology, the official journal of the World Molecular Imaging Society. He also led the scientific group who helped develop FDA guidelines for approval of diagnostic PET radiopharmaceuticals for cancer, heart and brain diseases, and the resulting federal law mandates (FDAMA 97). Dr. Barrio has written over 330 scientific publications and 30 book chapters. Dr. Barrio received his Ph.D. in Biochemistry at the University of Buenos Aires and a Ph.D. in Chemistry from the University of Illinois.